Key Liver Values to Monitor with Tigecycline
Tigecycline, an IV glycylcycline antibiotic for complicated infections, carries a risk of liver enzyme elevations. Monitor these liver function tests (LFTs) before starting therapy, periodically during treatment (e.g., weekly), and at discontinuation, especially in patients with baseline liver issues or prolonged use:
- ALT (alanine aminotransferase): Primary marker for hepatocellular injury; tigecycline often causes asymptomatic rises.
- AST (aspartate aminotransferase): Tracks alongside ALT; elevations >3x upper limit of normal (ULN) warrant closer watch.
- ALP (alkaline phosphatase): For cholestatic patterns, though less common.
- Total bilirubin: Signals potential severe injury if elevated with transaminases.
- PT/INR: Assesses synthetic function in at-risk cases.
Discontinue if ALT/AST exceed 10x ULN or if bilirubin rises significantly with symptoms like jaundice.[1][2]
Why Tigecycline Affects Liver Values
Hepatotoxicity occurs in 1-10% of patients, typically mild and reversible. Mechanism involves mitochondrial toxicity from tigecycline's interference with bacterial protein synthesis, extending to host cells. Risk factors include fatty liver, alcohol use, or combo with other hepatotoxins.[2][3]
How Often and When to Check
- Baseline: Full LFT panel.
- During therapy: Every 3-7 days for courses >14 days; more frequent if abnormalities emerge.
- Post-treatment: Repeat if peaks occurred.
Adjust dosing in Child-Pugh C cirrhosis (50% reduction); no adjustment for mild/moderate impairment.[1]
What If Values Are Elevated?
Mild rises (2-5x ULN) often resolve without stopping; monitor closely. Severe cases (>8x ULN) require immediate halt and supportive care. Rare hepatic failure reported (<0.1%). No specific antidote.[2]
Tigecycline vs. Other Antibiotics' Liver Risks
| Antibiotic | Hepatotoxicity Rate | Common Pattern |
|------------|---------------------|---------------|
| Tigecycline | 1-10% | Mixed hepatocellular |
| Doxycycline | <1% | Mild transaminitis |
| Vancomycin | 1-5% | Cholestatic |
| Fluoroquinolones (e.g., levofloxacin) | 0.1-2% | Hepatocellular |
Tigecycline has higher transaminase elevation risk than tetracyclines but lower than some alternatives like amoxicillin-clavulanate.[3]
Patient Factors That Increase Risk